Kidney Thrombotic Microangiopathy After COVID-19 Associated With Gene Mutation.
(2021) Kidney International Reports — Vol. 6, n° 6, p. 1732-1737 (2021)
Files
kidneythromboticmicroabgiopathy.pdf
Open Access - Adobe PDF
- 1.05 MB
Details
- Authors
- Abstract
- (en) Acute kidney injury (AKI) is not uncommon in patients with coronavirus disease 2019 (COVID-19), but thrombotic microangiopathy (TMA) linked to COVID-19 has been exceptionally reported in another patient.1 However, COVID-19–infected patients can develop proteinuria (44%), hematuria (27%), or AKI (5.1%).2 We report a case of atypical hemolytic uremic syndrome (aHUS) associated with COVID-19. This case highlights the importance of a rapid diagnosis, a good medical history, and a genetic analysis to optimize the management of this rare disease. We discuss the role of complement pathways in the pathophysiology of IgA nephropathy and COVID-19 infection. The treatment of aHUS usually requires the use of therapeutic plasma exchange (TPE) and eculizumab, a monoclonal antibody C5 inhibitor that drastically changed the prognosis of TMA. We also wanted to know if TPE impedes natural humoral immunity against COVID-19.
- Affiliations
Citations
Mat, O., Ghisdal, L., Massart, A., Aydin, S., Goubella, A., Blankoff, N., Gankam, F., Debelle, F., & Mat, Q. (2021). Kidney Thrombotic Microangiopathy After COVID-19 Associated With Gene Mutation. Kidney International Reports, 6(6), 1732-1737. https://doi.org/10.1016/j.ekir.2021.03.897 (Original work published 2021)